Abstract: Systems and methods that dynamically distribute status, cartridge movement and other types of requests and communications from a library manager to one or more libraries of a library string based on target or subject libraries in the requests. Upon receiving and/or generating a request, the library manager determines whether active connections (e.g., control paths) are available from the library manager substantially directly to the subject libraries and then distributes the requests over such active connections when available. When such active connections are unavailable, the library manager may distribute such requests over active connections to non-subject libraries which may forward such requests to the subject libraries via an inter-library communication interconnect.

Abstract: The disclosure relates to nutritional supplements to be administered to, or to be taken by, women desiring to become pregnant, and pregnant and nursing women, so that a woman (and any fetus) will be nutritionally supplemented before, during and after the gestation period. The nutritional supplements have a blend of folic acid, lycopene and co-enzyme QIO, optionally docosahexaenoic acid, and other vitamins and minerals, and a nutritionally acceptable carrier therefor, but are free or substantially free of other materials in nutritionally effective amounts. Specific nutritional supplements are described.

Abstract: Systems and methods that dynamically distribute status, cartridge movement and other types of requests and communications from a library manager to one or more libraries of a library string based on target or subject libraries in the requests. Upon receiving and/or generating a request, the library manager determines whether active connections (e.g., control paths) are available from the library manager substantially directly to the subject libraries and then distributes the requests over such active connections when available. When such active connections are unavailable, the library manager may distribute such requests over active connections to non-subject libraries which may forward such requests to the subject libraries via an inter-library communication interconnect.

Abstract: The present invention relates to different nutritional supplements to be administered to, or taken by, pregnant women during the first, second and third trimesters of pregnancy.

Abstract: The present invention relates to different nutritional supplements to be administered to, or taken by, pregnant women during the first, second and third trimesters of pregnancy.

Abstract: The present invention relates to nutritional supplements to be administered to, or to be taken by, women desiring to become pregnant, and pregnant and nursing women. The nutritional supplements of this invention have a unique blend of vitamins, minerals, lycopene, co-enzyme Q10, DHA, docusate (such as docusate sodium), folic acid, and a nutritionally acceptable carrier therefor. The invention includes specific nutritional supplements for the uses set forth above.

Abstract: The present invention relates to nutritional supplements to be administered to, or to be taken by, women desiring to become pregnant, and pregnant and nursing women. The nutritional supplements of this invention have a unique blend of vitamins, minerals, lycopene, co-enzyme Q10, DHA, docusate (such as docusate sodium), folic acid, and a nutritionally acceptable carrier therefor. The invention includes specific nutritional supplements for the uses set forth above.

Abstract: The present invention relates to nutritional supplements to be administered to, or to be taken by, women desiring to become pregnant, and pregnant and nursing women. The nutritional supplements of this invention have a unique blend of vitamins, minerals, lycopene, co-enzyme Q10, DHA, docusate (such as docusate sodium), folic acid, and a nutritionally acceptable carrier therefor. The invention includes specific nutritional supplements for the uses set forth above.

Abstract: The present invention relates to methods to treat and/or prevent optic nerve damage in a subject by administering a composition comprising a crystallin agonist.

Abstract: This invention relates to an animal model for human ocular disease, particularly glaucoma. The invention provides methods for determining the causes of human ocular diseases, and specifically provides methods for the anatomical, histochemical and molecular biological evaluation of the effects of elevated intraocular pressure on various tissues in mammalian eyes in vivo. The invention also provides methods for non-invasively measuring intraocular pressure and for evaluating the efficacy of treatment stategies for glaucoma involving glaucoma-relieving drugs.

Abstract: This invention is a device for microvascular injection and a method for treating glaucoma using the device. The device comprises a reservoir attached to a blunted needle connected to a flexible tapered tubing, at the end of which is positioned a microneedle or micropipette for inserting into small blood vessels. The invention also provides a method for treating glaucoma and other diseases wherein microinjection of disease-ameliorating drugs into small blood vessels and their capillary beds would be therapeutically effective.

Abstract: A method of detecting cancer in mammals which comprises precipitating at least a portion of the proteins in a serum sample from a mammal and then measuring the rate at which said precipitated proteins are re-solubilized.

Abstract: A process for preparing CoA-SPC Bakers' yeast extract which comprises:lysing Bakers' yeast cells;separating the Bakers' yeast cell lysate into solid and supernatant fractions wherein said solid fraction is substantially free of t-factor;treating said solid fraction to solubilize insoluble proteinaceous material other than the insoluble CoA-SPC;separating said solubilized proteinaceous materials from the fraction containing said insoluble CoA-SPC; andcontacting said fraction containing said insoluble CoA-SPC with said supernatant fraction containing t-factor to produce soluble CoA-SPC.

Abstract: CoA-SPC Bakers' yeast extract which is substantially free of proteolytic enzymes.

Abstract: A specific type of protein, which has been designated B-protein (Bucovaz-protein), is present in most serum of individuals with cancer. The B-protein interacts with a low molecular weight protein component, which is released by the coenzyme A-synthesizing protein complex (CoA-SPC) of Bakers' yeast during the course of CoA synthesis. This low molecular weight protein, for purposes of identification, is referred to as binding protein. The binding protein has a molecular weight of 10,000 to 15,000. Interaction of radioactively labeled binding protein of CoA-SPC with the B-protein of serum provides a marker for the detection of cancer. Of 3005 serums assayed, which included 908 patients diagnosed as having cancer, the B-protein assay agreed with the clinical diagnosis in more than 89% of the cases.

Abstract: A specific type of protein, which has been designated B-protein (Bucovaz-protein), is present in most serum of individuals with cancer. The B-protein interacts with a low molecular weight protein component, which is released by the coenzyme A-synthesizing protein complex (CoA-SPC) of Bakers' yeast during the course of CoA synthesis. This low molecular weight protein, for purposes of identification, is referred to as binding protein. The binding protein has a molecular weight of 10,000 to 15,000. Interaction of radioactively labeled binding protein of CoA-SPC with the B-protein of serum provides a marker for the detection of cancer. Of 3005 serums assayed, which included 908 patients diagnosed as having cancer, the B-protein assay agreed with the clinical diagnosis in more than 89% of the cases.